Fisher Asset Management LLC Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fisher Asset Management LLC boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 452,497 shares of the biopharmaceutical company's stock after buying an additional 78,145 shares during the quarter. Fisher Asset Management LLC owned 0.68% of Celldex Therapeutics worth $11,435,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after purchasing an additional 1,167,659 shares during the period. Jennison Associates LLC lifted its stake in Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock worth $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Readystate Asset Management LP purchased a new position in shares of Celldex Therapeutics during the third quarter valued at approximately $6,102,000. Sovran Advisors LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter valued at approximately $2,867,000. Finally, Sphera Funds Management LTD. raised its holdings in shares of Celldex Therapeutics by 35.5% in the third quarter. Sphera Funds Management LTD. now owns 419,103 shares of the biopharmaceutical company's stock worth $14,245,000 after buying an additional 109,838 shares during the period.

Remove Ads

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.66 during trading on Friday, reaching $20.67. 588,861 shares of the company's stock traded hands, compared to its average volume of 900,222. Celldex Therapeutics, Inc. has a 12-month low of $18.61 and a 12-month high of $49.65. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -8.04 and a beta of 1.76. The company's 50 day simple moving average is $23.48 and its two-hundred day simple moving average is $28.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on CLDX. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price objective for the company. Finally, The Goldman Sachs Group dropped their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research note on Monday. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $55.38.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.